Abstract:Intracellularly acting ligands of G protein-coupled receptors (GPCRs) are gaining significant interest in GPCR drug discovery. In this study, we report the development of the fluorescent ligand Mz437 (4) targeting the CC chemokine receptor CCR7 at an intracellular allosteric site. We demonstrate its experimental power by applying 4 to identify two improved intracellular CCR7 antagonists, SLW131 (10) and SLW132 (21m), developed by converting two weakly active antagonists into single- or double-digit nanomolar ligands with minimal modifications. The thiadiazoledioxide 10 was derived from the CCR7 antagonist Cmp2105 by removing a methyl group from the benzamide moiety, while the squaramide 21m was obtained from the CXCR1/CXCR2 antagonist and clinical candidate navarixin by replacing the ethyl substituent by a tert-butyl group to engage a lipophilic subpocket. We show that 10 and 21m qualify to probe CCR7 biology both in recombinant cells and in the endogenous signaling environment of immune cells. Our novel probes are expected to facilitate the design of next-generation intracellular CCR7 ligands and serve as molecular tools to interrogate CCR7 biology in human and murine endogenous settings.

What problem does this paper attempt to address?

This paper aims to address the key challenges encountered in drug discovery for CC chemokine receptor 7 (CCR7), especially in drug discovery for its intracellular allosteric site (IABS). Specifically, the researchers developed a fluorescent probe, Mz437, for identifying and optimizing intracellular allosteric antagonists of CCR7. Through this method, they successfully discovered two improved CCR7 antagonists, SLW131 (10) and SLW132 (21m), which showed significant affinity and selectivity both inside and outside the cell. ### Main problems 1. **Lack of effective CCR7 antagonists**: - The currently known CCR7 antagonists are not very effective, especially in their action on the intracellular allosteric site. Therefore, the development of highly effective CCR7 antagonists is of great significance for the treatment of related diseases. 2. **Improving the affinity and selectivity of antagonists**: - Through structural modification, the researchers hope to find new CCR7 antagonists that can significantly improve affinity and selectivity. For example, by removing the methyl group in Cmp2105, SLW131 (10) with a 10 - fold increased affinity was obtained. 3. **Validating the biological functions of new compounds**: - The researchers need to validate the biological functions of the newly discovered antagonists in recombinant cells and primary immune cells to ensure that they can function in a complex physiological environment. ### Solutions 1. **Developing the fluorescent probe Mz437**: - Through structural design and synthesis, the researchers developed the fluorescent probe Mz437, which can bind to the intracellular allosteric site of CCR7 and is used for high - throughput screening and affinity determination. 2. **Structure - activity relationship (SAR) studies**: - By performing structural modifications on Cmp2105 and navarixin, the researchers synthesized multiple derivatives and evaluated their affinity and selectivity through various experimental methods. 3. **Intracellular and extracellular experiments**: - Using the NanoBRET technology, the researchers carried out saturation binding experiments and competitive binding experiments both inside and outside the cell to validate the affinity and selectivity of the new compounds. ### Results - **SLW131 (10)**: By removing the methyl group in Cmp2105, SLW131 (10) with a 10 - fold increased affinity was obtained. - **SLW132 (21m)**: By replacing the ethyl group in navarixin with a tert - butyl group, SLW132 (21m) with a significantly increased affinity was obtained. - **Biological function validation**: The newly discovered antagonists showed good biological functions in both recombinant cells and primary immune cells and were able to function in a complex physiological environment. In conclusion, through the development of the fluorescent probe Mz437 and detailed SAR studies, this paper successfully discovered two improved CCR7 antagonists, providing new tools and candidate molecules for drug development related to CCR7 - associated diseases.

A fluorescent probe enables the discovery of improved antagonists targeting the intracellular allosteric site of the chemokine receptor CCR7

Fluorophore-Labeled Pyrrolones Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR1

Identification of a novel allosteric binding site in the CXCR2 chemokine receptor

Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis

Structural And Biological Characterizations Of Novel High-Affinity Fluorescent Probes With Overlapped And Distinctive Binding Regions On Cxcr4

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist

Identification of novel human CC chemokine receptor 8 (CCR8) antagonists via the synthesis of naphthalene amide and sulfonamide isosteres

Synthesis and Application of Fluorescein‐ and Biotin‐Labeled Molecular Probes for the Chemokine Receptor CXCR4

Labeling of CC Chemokine Receptor 2 with a Versatile Intracellular Allosteric Probe

Exploring the CXCR3 Chemokine Receptor with Small-Molecule Antagonists and Agonists

A Novel Cxcr4-Selective High-Affinity Fluorescent Probe and Its Application in Competitive Binding Assays

Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists

Abstract 4: Discovery of Novel and Highly Potent Small Molecule Inhibitors of Chemokine Receptor CXCR4

Chimeric Protein Probes for C5a Receptors Through Fusion of the Anaphylatoxin C5a Core Region with a Small-Molecule Antagonist

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

Fragment-based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction.

Multiplex Detection of Functional G Protein-Coupled Receptors Harboring Site-Specifically Modified Unnatural Amino Acids.

Studying allosteric regulation of chemokines and antagonists using a nanoscale hCCR3 receptor sensor

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5